Brief: Contrafect announces publication on Exebacase and CF-296 demonstrating potent in vivo antimicrobial activity in implant-associated MRSA osteomyelitis
15/08/2022 13:29
Aug 15 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES PUBLICATION ON EXEBACASE AND CF-296
DEMONSTRATING POTENT IN VIVO ANTIMICROBIAL ACTIVITY IN
IMPLANT-ASSOCIATED MRSA OSTEOMYELITIS
Source text for Eikon: ID:nGNXl45vm
Further company coverage: CFRX.O
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370